Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

Source: OncLive, October 2020

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of pembrolizumab (Keytruda) in combination with selinexor (Xpovio) in advanced melanoma.

During the 2020 ESMO Virtual Congress, initial findings from a phase 1b study (NCT02419495) showed significant clinical activity in patients with metastatic melanoma.

Notably, no new safety signals were observed with the combination, which allowed the study to meet its primary objective of safety and tolerability, Glitza Olivia explains.

READ THE ORIGINAL FULL ARTICLE